Drug intelligence / Profile preview

NK-92 + ALT-803

Development stage: Unknown
Lead developer: ImmunityBio
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

**NK-92 + ALT-803** is a combination immunotherapy consisting of NK-92 (a clinically validated, allogeneic natural killer cell line, also known as haNK) and ALT-803 (also known as N-803 or Anktiva, an interleukin-15 [IL-15] superagonist complex). ALT-803 is an IL-15N72D/IL-15 receptor alpha sushi domain/Fc fusion protein designed to stimulate and expand NK cells and CD8+ T cells, enhancing immune-mediated tumor cell killing. NK-92 cells are expanded and activated NK cells engineered for cytotoxic activity against tumor cells. In the combination, ALT-803 serves as a cytokine to further potentiate NK-92 cell proliferation, survival, and anti-tumor activity, potentially overcoming resistance to checkpoint inhibitors or prior immunotherapy. This combination is under investigation for various advanced solid tumors and hematologic malignancies, including trials in Merkel cell carcinoma and non-small cell lung cancer after checkpoint inhibitor failure[3][4][5].

Brand names: Anktiva + NK-92
Other names: NK-92/haNK + N-803/ALT-803

Targets

IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)

Beyond the preview

Go deeper on NK-92 + ALT-803.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NK-92 + ALT-803.

Explore the full profile